Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit Number: 432, Houston, TX 77030, USA.
Invest New Drugs. 2012 Aug;30(4):1802-11. doi: 10.1007/s10637-011-9750-1. Epub 2011 Oct 11.
Standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC) has primarily consisted of traditional cytotoxic chemotherapy, although use of targeted therapies has been approved in specific settings. Antiangiogenic agents represent a promising therapeutic strategy for treatment of advanced NSCLC. Bevacizumab is currently approved when given in combination with first-line platinum-based therapy in selected patients with nonsquamous NSCLC. Bevacizumab may also provide benefit in other clinical settings, as a part of a combination or maintenance strategy. Other antiangiogenic agents under development, including multi-targeted kinase inhibitors (MTKIs) and antibody-based agents, have exhibited mixed results in the NSCLC population. Published efficacy and safety data from clinical trials for antiangiogenic agents are reviewed, with an emphasis on novel agents and novel settings for established agents. Identification of biomarkers associated with improved efficacy may help select patients likely to receive the most benefit from these agents and may improve outcomes through development of personalized therapeutic strategies.
晚期或转移性非小细胞肺癌（NSCLC）的标准治疗主要包括传统细胞毒性化疗，尽管在某些情况下已批准使用靶向治疗。抗血管生成药物代表了治疗晚期 NSCLC 的一种有前途的治疗策略。贝伐珠单抗目前被批准与选定的非鳞状 NSCLC 患者的一线铂类治疗联合使用。贝伐珠单抗也可能在其他临床环境中提供获益，作为联合或维持策略的一部分。其他正在开发的抗血管生成药物，包括多靶点激酶抑制剂（MTKIs）和基于抗体的药物，在 NSCLC 人群中显示出混合结果。本文回顾了抗血管生成药物临床试验的疗效和安全性数据，重点介绍了新型药物和已上市药物的新应用。鉴定与疗效改善相关的生物标志物可能有助于选择可能从这些药物中获益最大的患者，并通过制定个体化治疗策略来改善结局。
